相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
Irene Capelli et al.
JOURNAL OF NEPHROLOGY (2020)
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
Akifumi Kurata et al.
ADVANCES IN THERAPY (2020)
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
Matteo Serenelli et al.
JACC-HEART FAILURE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN) Phase 3 Randomized Controlled Clinical Trial
Sadayoshi Ito et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment
Roland Heinig et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Jonatan Barrera-Chimal et al.
KIDNEY INTERNATIONAL (2019)
Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
Sadayoshi Ito et al.
JOURNAL OF HUMAN HYPERTENSION (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
Sadayoshi Ito et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
Hiromi Rakugi et al.
HYPERTENSION RESEARCH (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Emerging Drug Classes and Their Potential Use in Hypertension
Michel Azizi et al.
HYPERTENSION (2019)
Pharmacokinetics, Metabolism, and Excretion of [14C] Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
Makiko Yamada et al.
DRUG METABOLISM AND DISPOSITION (2019)
Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
Chris J. Kapelios et al.
HEART FAILURE REVIEWS (2019)
Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
Abdus Sattar Bhuiyan et al.
HYPERTENSION RESEARCH (2019)
Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
Sadayoshi Ito et al.
HYPERTENSION (2019)
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease
Iris E. Beldhuis et al.
JACC-HEART FAILURE (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Evaluation and Management of Right-Sided Heart Failure A Scientific Statement From the American Heart Association
Marvin A. Konstam et al.
CIRCULATION (2018)
Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
N. Tofte et al.
DIABETIC MEDICINE (2018)
Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo
Roland Heinig et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2018)
Medical Therapy for Heart Failure With Reduced Ejection Fraction
Stephen J. Greene et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure A systematic review and meta-analysis
Hui Pei et al.
MEDICINE (2018)
Primary Aldosteronism: Practical Approach to Diagnosis and Management
James Brian Byrd et al.
CIRCULATION (2018)
Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
Michael Gerisch et al.
DRUG METABOLISM AND DISPOSITION (2018)
Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology
Alessandro Cannavo et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)
Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease
Chen-Ta Yang et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Brain-Type Natriuretic Peptide and Amino-Terminal Pro-Brain-Type Natriuretic Peptide Discharge Thresholds for Acute Decompensated Heart Failure
Casey N. McQuade et al.
ANNALS OF INTERNAL MEDICINE (2017)
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF
Joao Pedro Ferreira et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
Clyde W. Yancy et al.
JOURNAL OF CARDIAC FAILURE (2017)
Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease
Evan B. Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Mineralocorticoid receptor antagonists: 60 years of research and development
Peter Kolkhof et al.
JOURNAL OF ENDOCRINOLOGY (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
Greg H. Tesch et al.
FRONTIERS IN PHARMACOLOGY (2017)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2016)
Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
Peter Bramlage et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension One-Year Outcomes of Randomized PRAGUE-15 Study
Jan Rosa et al.
HYPERTENSION (2016)
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease
Naoki Sato et al.
CIRCULATION JOURNAL (2016)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies
Silvia Lentini et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
Shigehiro Katayama et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
Nonsteroidal antagonists of the mineralocorticoid receptor
Peter Kolkhof et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2015)
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
Kiyoshi Arai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
Larbi Amazit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams et al.
LANCET (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Exploring the Role of Aldosterone in Right Ventricular Function
Alexis Harrison et al.
CANADIAN JOURNAL OF CARDIOLOGY (2014)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial
Katsuyuki Ando et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Aldosterone regulates Na+, K+ ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor
Sarah A. Salyer et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial
Nicolas Girerd et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction The Aldo-DHF Randomized Controlled Trial
Frank Edelmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Eplerenone-Mediated Aldosterone Blockade Prevents Renal Fibrosis by Reducing Renal Inflammation, Interstitial Cell Proliferation and Oxidative Stress
Hui Chen et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2013)
PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
Stephen Orena et al.
FRONTIERS IN PHARMACOLOGY (2013)
Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Lars Baerfacker et al.
CHEMMEDCHEM (2012)
Mechanisms of ligand specificity of the mineralocorticoid receptor
Peter J. Fuller et al.
JOURNAL OF ENDOCRINOLOGY (2012)
Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure
Orly Vardeny et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Aldosterone, mineralocorticoid receptor, and heart failure
Smail Messaoudi et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
Peter Kolkhof et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Y. Miao et al.
DIABETOLOGIA (2011)
Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT) A Randomized, Double-Blind, Placebo-Controlled Trial
Jan Vaclavik et al.
HYPERTENSION (2011)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
Jean M. Nappi et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2011)
A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
Jerome Fagart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Aldosterone and Mineralocorticoid Receptors in the Cardiovascular System
John W. Funder
PROGRESS IN CARDIOVASCULAR DISEASES (2010)
Serum Cortisol as a Useful Predictor of Cardiac Events in Patients With Chronic Heart Failure The Impact of Oxidative Stress
Masayuki Yamaji et al.
CIRCULATION-HEART FAILURE (2009)
Use of Aldosterone Antagonists in Heart Failure
Nancy M. Albert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Incidence and predictors of hyperkalemia in patients with heart failure
Akshay S. Desai et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Effect of spironolactone on blood pressure in subjects with resistant hypertension
Neil Chapman et al.
HYPERTENSION (2007)
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus
Christine Guo et al.
ENDOCRINOLOGY (2006)
Mechanisms of mineralocorticoid action
PJ Fuller et al.
HYPERTENSION (2005)
The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure
KB Shah et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment
WR Ravis et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Clinical factors associated with hyperkalemia in patients with congestive heart failure
FH Ramadan et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2005)
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats
G Fujisawa et al.
KIDNEY INTERNATIONAL (2004)
Rates of hyperkalemia after publication of the randomized aldactone evaluation study
DN Juurlink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure
PM Mottram et al.
CIRCULATION (2004)
Aldosterone: Direct effects on and production by the heart
PC White
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
ER Blasi et al.
KIDNEY INTERNATIONAL (2003)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Beneficial neurohormonal profile of spironolactone in severe congestive heart failure -: Results from the RALES neurohormonal sub-study
MF Rousseau et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
MH Weinberger et al.
AMERICAN JOURNAL OF HYPERTENSION (2002)
Mechanisms of disease - Aldosterone in congestive heart failure
KT Weber
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Induction of cardiac fibrosis by aldosterone
P Lijnen et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2000)
分享论文
